๐ฐ William Bliar News
William Bliar News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from William Bliar. Real-time updates on events, politics, business and more.
January 17, 2024
FDA approves CRISPR Therapeutics/Vertex's Casgevy a gene-edited cell therapy for transfusion-dependent beta-thalassemia. Vertex's swift launch strategy targets a network of treatment centers across the U.S.
January 3, 2024
William Bliar has initiated coverage on Enovis Corp (NYSE: ENOV), a medical technology company focusing on the orthopedics market valued at approximately $25 billion, experiencing steady growth, especially in sub-categories such as extremities, which are growing rapidly due to
January 3, 2024
William Bliar has initiated coverage on Enovis Corp ENOV, a medical technology company focusing on the orthopedics market valued at approximately $25 billion,โฆ
December 19, 2023
Monday, Lantheus Holdings Inc LNTH and POINT Biopharma Global Inc PNT reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastaticโฆ
December 19, 2023
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c
August 24, 2023
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the phase 3 CABINET pivotal trial early due to a dramatic improvement in efficacy that was